Control Bionics Ltd. engages in the manufacture, design, and sale of wireless wearable electromyography (EMG) based augmentative and alternative communication (AAC) technology. The company is headquartered in Sydney, New South Wales. The firm is engaged in the development, commercialization, and sale of assistive communications technology systems within the disability sector. The company assists patients whose ability to communicate verbally or through text and social media is compromised by illnesses, such as motor neuron disease and amyotrophic lateral sclerosis. Its NeuroNode technology is a wireless wearable device that detects minute signals sent from the brain to any skeletal muscle and is captured as Electromyography output. This output is then sent wirelessly through the NeuroNode to a personal computer, enabling speech and other computer-controlled functions, such as email and texting. Its core systems include NeuroNode Trilogy, NeuroNode Duo and Eye-gaze Duo. Its technology is integrated with eye gaze technology whereby the eye gaze enables a cursor to be moved about a computer screen, driven like a mouse, and the NeuroNode acts as like the mouse button.